1. Gastro-Intestinal System | 2. Cardiovascular System | 3. Respiratory System | 4. Central Nervous System | 5. Antimicrobials | 6. Endocrine System | 7. Obstetrics, Gynaecology & Urology | 8. Malignant Disease & Immunosuppression | 9. Nutrition & Blood | 10. Musculoskelatal & Joint Diseases | 11. Opthalmology | 12. Ear, Nose & Oropharynx | 13. Dermatology | 14. Immunology & Vaccines | 15. Anaesthetics | GP Centre Home
Malignant Disease & Immunosuppression
| IMMUNE SYSTEM | ||
| 1 Immune System Disorders and Transplantation | ||
| IMMUNOSUPPRESSANTS – Antimetabolites | ||
| AZATHIOPRINE | 25mg & 50mg Tablets
| Link to Shared Care Guideline for approved indications Shared Care Agreement Communication Form APC traffic light status: AMBER |
| 50mg Injection | . | |
| IMMUNOSUPPRESSANTS – Calcineurin inhibitors and related drugs | ||
| CICLOSPORIN | Capsules 10mg, 25mg, 50mg & 100mg 100 mg / ml Oral Liquid | There are a number of brands of this drug. If initiating oral ciclosporin, Capsorin brand is 1st choice. Avoid unnecessary switching between brands because of pharmacokinetic differences (in transplant patients). Minimum 1 month supply for rheumatology & dermatology indications before GP can accept shared care prescribing. Link to Shared Care Guideline for approved indications Shared Care Agreement Communication FormAPC traffic light status: AMBER |
| 50 mg Injection | . | |
| TACROLIMUS | Capsules 500micrograms, 1mg & 5mg | APC traffic light status: RED |
| IMMUNOSUPPRESSANTS – Purine Synthesis inhibitors | ||
| MYCOPHENOLATE | 250mg Capsules 500 mg Tablets 1 g / 5ml Suspension | There are a number of brands of this drug. Avoid unnecessary switching because of pharmacokinetic differences (in transplant patients). Minimum 3 months supply for non-transplant indications before GP can accept shared care prescribing. Link to Shared Care Guideline for approved indications Shared Care Agreement Communication FormNon-transplant indications APC traffic light status: AMBER (Transplant APC traffic light status:Red) |
| 1.1 Multiple Sclerosis | ||
| IMMUNOSTIMULANTS – Interferons | ||
| INTERFERON BETA-1a | REBIF: 22micrograms (6MU) Pre-filled syringe 44micrograms (12MU) Pre-filled syringe AVONEX: 300micrograms (6MU) Injection (Powder for reconstitution) | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis APC traffic light status: RED |
| IMMUNOSTIMULANTS – Other | ||
| GLATIRAMER | 20mg/ml, 40mg/ml pre-filled syringes | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis APC traffic light status: RED |
| IMMUNOSUPPRESSANTS -Immunomodulating Drugs | ||
| DIMETHYL FURATE (TECFIDERA) | 120mg, 240mg Capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE NICE TAG320 Dimethyl Fumerate for relapsing-remitting MS APC traffic light status: RED |
| IMMUNOSUPPRESSANTS – Monoclonal Antibodies – Anti-Lymphoctes | Biologics must be prescribed by brand. The brand providing best value in local health economy should be prescribed for all new patients. Following patient consent, existing patients should be switched to the rand providing best value in local health economy. | |
| ALEMTUZUMAB | 10mg/ml, 30mg/ml solution for infusion | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. IFR required if for Aplastic anaemia – see APC statement below. NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis PCN statement: Alemtuzumab for Aplastic AnaemiaAPC traffic light status: RED |
| NATALIZUMAB (TYSABRI) | IV Infusion 20mg/ml Concentrate for Infusion | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE NICE TA127 Natalizumab for relapsing-remitting MS APC traffic light status: RED |
| IMMUNOSUPPRESSANTS – Pyrimidine Synthesis Inhibitors | ||
| TERIFLUNOMIDE (AUBAGIO) | 7mg & 14mg Oral Tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE NICE TA303 Teriflunoide for relapsing-remitting MS APC traffic light status: RED |
| MALIGNANT DISEASE | ||
| 1 Antibody Response Malignancy | ||
| ANTINEOPLASTIC DRUG – Monoclonal Antibodies | ||
| ATEZOLIZUMAB | 1200mg/20ml concentrate for solution | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE CDF. TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer APC traffic light status: RED |
| BLINATUMOMAB | vials 38.5micrograms | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE APC traffic light status: RED |
| BRENTUXIMAB VEDOTIN | 50mg powder for concentrate for solution for infusion | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE through CDF. NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma APC traffic light status: RED |
| CEMIPLIMAB | 350mg/7ml vials | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE through CDF. APC traffic light status: RED |
| DARATUMUMAB | 100mg/5ml solution | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE CDF. NICE TA 510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma APC traffic light status: RED |
| DURVALUMAB | 120mg/2.4ml vials 500mg/10ml vials | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE APC traffic light status: RED |
| GEMTUZUMAB OZOGAMICIN | 5mg vial | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. IFR required if for Aplastic anaemia – see PCN statement below. NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia APC traffic light status: RED |
| INOTUZUMAB OZOGAMICIN | 1mg vial | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| NIVOLUMAB | 1mg/ml solution for infusion | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer APC traffic light status: RED |
| OBINUTUZUMAB | 1000mg/40ml concentrate for solution for infusion vials | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE (CDF). NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab NICE TA513 Obinutuzumab for untreated advanced follicular lymphoma NICE TA 629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab APC traffic light status: RED |
| PEMBROLIZUMAB | 100mg/4ml concentrate for solution for infusion 50mg powder for concentrate for solution | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE (CDF). NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer NICE TA336 – Pembrolizumab for advanced melanoma not previously treated with ipilimumab NICE TA357 – Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab NICE TA428 – Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence APC traffic light status: RED |
| PERTUZUMAB | 420mg vial | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE through CDF. NICE TA: neoadjuvant treatment of HER2-positive breast cancer NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer APC traffic light status: RED |
| RITUXIMAB | 100mg/10ml concentrate for solution 500mg/50ml concentrate for solution | Truxima® currently provides the best value to the local health economy. Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA193 -Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia NICE TA174 – Rituximab for the first-line treatment of chronic lymphocytic leukaemia NICE TA226 -Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma NICE TA243 – Rituximab for the first-line treatment of stage III-IV follicular lymphoma NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma APC traffic light status: RED |
| TRASTUZUMAB (Herceptin) | 120mg/ml solution for injection 150mg poweder for solution for infusion | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer APC traffic light status: RED |
| TRASTUZUMAB EMTANSINE | 100mg, 160mg powder for solution for infusion | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE/CDF APC traffic light status: RED |
| 3 Cytotoxic Response Malignancy | ||
| BUSULFAN | 2 mg Tablets | APC traffic light status: RED |
| CHLORAMBUCIL | 2 mg Tablets | NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia APC traffic light status: RED |
| CYCLOPHOSPHAMIDE | 50mg Tablets Injection 500mg Vials & 1g Vials | APC traffic light status: RED |
| DACARBAZINE | 200mg & 1g Vials | APC traffic light status: RED |
| ESTRAMUSTINE | 140 mg Capsules | APC traffic light status: RED |
| IFOSFAMIDE | 1g & 2g Injection | APC traffic light status: RED |
| LOMUSTINE | 40 mg Capsules | APC traffic light status: RED |
| MELPHALAN | 2 mg Tablets 50 mg Injection | APC traffic light status: RED |
| TREOSULFAN | 1g, 5g powder for solution for injection | NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| ANTINEOPLASTIC DRUGS – Anthracyclines and Related drugs | ||
| DAUNORUBICIN | 20 mg Injection | APC traffic light status: RED |
| CYTARABINE with DAUNORUBICIN (Vyxeos) | 44mg/100mg powder for concentrate for solution for infusion vials | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA 552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia APC traffic light status: RED |
| DOXORUBICIN | 2mg/ml 5ml Vials & 25ml Vials | APC traffic light status: RED |
| EPIRUBICIN | 2mg/ml 5ml & 25ml Vials | APC traffic light status: RED |
| IDARUBICIN | 5mg, 10mg & 25mg Capsules | APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Antimetabolites | ||
| CAPECITABINE | 150mg & 500 mg Tablets | Prescribed by Specialist Centre (Guildford) APC traffic light status: RED |
| CLADRIBINE | 10 mg Injection | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE for multiple sclerosis. NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis Hairy Cell Leukaemia APC traffic light status: RED |
| CYTARABINE | 100 mg /ml Injection 100 mg / 5ml Injection | APC traffic light status: RED |
| FLUDARABINE PHOSPHATE | 10 mg Tablets 50 mg Injection | NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant APC traffic light status: RED |
| FLUOROURACIL | 250mg Capsules 25mg / ml Injection 50mg / ml Injection 10ml & 50ml Vials | NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer APC traffic light status: RED |
| GEMCITABINE | 200mg & 1g Injection | NICE TA116: Gemcitabine for the treatment of metastatic breast cancer APC traffic light status: RED |
| MERCAPTOPURINE | 10mg & 50mg Tablets | Used for AcuteLymphLeuk (adults&children). Azathioprine / 6-MU Shared Care [IBD] Unlicensed APC traffic light status: AMBER |
| METHOTREXATE | Injection | Rheumatoid Aerthritis, Psoriatic arthritis, Psoriasis, Crohns disease APC traffic light status: AMBER |
| Injection | Oncology (Intrathecal for CNS Lymphoma) APC traffic light status: RED | |
| PEMETREXED | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer APC traffic light status: RED | |
| TIOGUANINE | 40mg Tablets | Haematology use only Non-formulary for all other indications including IBD (off-label use) – Non-formulary one off requests required. APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Cytotoxic Antibiotics & Related Substances | NOTES | |
| BLEOMYCIN | 15000 Unit Injection | APC traffic light status: RED |
| MITOMYCIN | 40mg For Bladder Instillation | APC traffic light status: RED |
| PENTOSTATIN | 10 mg Injection | APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Platinum Compounds | NOTES | |
| CARBOPLATIN | 10mg/ml Injection 15ml, 45ml & 60ml Vials | NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer APC traffic light status: RED |
| CISPLATIN | 1mg/ml Injection 50ml & 100ml Vials | NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Podophyllotoxin Derivatives | NOTES | |
| ETOPOSIDE | 50mg & 100mg Capsules 100 mg in 5ml Injection | APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Taxanes | NOTES | |
| DOCETAXEL | 80 mg in 2ml Injection | NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Vinca Alkaloids | NOTES | |
| VINBLASTINE SULPHATE | 10 mg Injection | APC traffic light status: RED |
| VINCRISTINE SULPHATE | 2 mg in 2ml Vial | APC traffic light status: RED |
| VINDESINE | 5mg Injection | APC traffic light status: RED |
| VINORELBINE | 10mg/ml 1ml & 5ml Vials | Used for LungCa & BreastCa. APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Other | ||
| ARSENIC TRIOXIDE | 10mg/10ml ampoules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia APC traffic light status: RED |
| ERIBULIN | 440micrograms/ml, 2ml injection | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE through CDF. NICE TA: locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens APC traffic light status: RED |
| HYDROXYCARBAMIDE (Hydroxyurea) | 500 mg Capsules | Myeloproliferative Disorders APC traffic light status: BLUE |
| PANOBINOSTAT | 10mg, 15mg, 20mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments APC traffic light status: RED |
| PROCARBAZINE | 50 mg Capsules | . |
| 3.1 Cystotoxic drug-induced side effects | ||
| DETOXIFYING DRUGS – Uroprotective Drugs | ||
| MESNA | 400mg Tablets 100mg/ml Injection | . |
| VITAMINS AND TRACE ELEMENTS – Folates | ||
| CALCIUM FOLINATE | 15mg Tablets 10mg/ml 5ml & 10ml vials | . |
| 3.1 Hyperuricaemia associated with cytotoxic drugs | ||
| DETOXIFYING DRUGS – Urate Oxidases | ||
| RASBURICASE | 1.5mg, 7.5mg vials for infusion | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| 4 Hormone Responsive Malignancy | ||
| ANTINEOPLASTIC DRUGS – Anti-Androgens | ||
| ABIRATERONE ACETATE | 500mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: BLUE |
| BICALUTAMIDE | 50 mg, 150mg Tablets | Prostate cancer APC traffic light status: BLUE (no information sheet) |
| ENZALUTAMIDE | 40mg Capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| FLUTAMIDE | 250 mg Tablets | . |
| CYPROTERONE ACETATE | 50 mg, 100mg Tablets | Blue (no information sheet) for prostate cancer treatment APC traffic light status: BLUE |
| OESTROGENS | ||
| DIETHYLSTILBESTROL | 1 mg Tablets | INTRON-A |
| PITUITARY AND HYPOTHALMIC HORMONES AND ANALOGUES – Anti-Gonadotrophin Releasing Hormones | ||
| DEGARELIX (Firmagon) | 80mg & 120mg S/C Injection | RESTRICTED : UROLOGY Team only Patients with/at risk of spinal cord compression SMC Restricted Approval Degarelix S/C injection every 28 days NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer APC traffic light status: BLUE |
| Somatostatin Analogues | ||
| LANREOTIDE | 30mg Injection(LA) 60mg Injection (Autogel) | RESTRICTED Use. CONSULTANT Only APC traffic light status: RED |
| OCTREOTIDE Injection | 50mcg, 100mcg & 500mcg Injection | APC traffic light status: RED |
| Progestogens | ||
| MEGESTROL ACETATE | 40 mg, 160mg Tablets | . |
| 4.1 Hormone Receptive Breast Cancer | ||
| ANTINEOPLASTIC DRUGS – Anti-Oestrogens | ||
| FULVESTRANT | 250mg/5ml solution for injection | NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (not recommended) NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (not recommended) APC traffic light status: RED |
| TAMOXIFEN | 10 mg, 20 mg Tablets 10 mg in 5ml Syrup | . |
| HORMONE ANTAGONISTS AND RELATED AGENTS – Aromatase Inhibitors | ||
| ANASTROZOLE | 1 mg Tablets | APC traffic light status: BLUE |
| EXEMESTANE | 25 mg Tablets | APC traffic light status: BLUE |
| LETROZOLE | 2.5 mg Tablets | APC traffic light status: BLUE |
| 5 IMMUNOTHERAPY RESPONSIVE MALIGNANCY | ||
| IMMUNOSTIMULANTS – Interferons | ||
| INTERFERON ALFA-2b(rbe) (INTRON-A) | 10 MU/ml Injection Cartridges for Multidose Pen | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE Guidance (peginterferon-alfa, interferon-alfa & ribavirin) Chronic Hepatitis C) APC traffic light status: RED |
| INTERFERON ALFA-2a(rba) (ROFERON-A) | Pre-filled Syringes 3MU, 4.5MU, 6MU | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE Guidance (peginterferon-alfa, interferon-alfa & ribavirin) Chronic Hepatitis C) APC traffic light status: RED |
| IMMUNOSUPPRESSANTS – Other | ||
| Bacillus Calmette-Guerin (BCG) | (OncoTICE) Strain BAGS For Bladder Instillation | |
| IMMUNOSUPPRESSANTS – Thalidomide and Related Anologues | ||
| LENALIDOMIDE (REVLIMID) | 2.5mg, 5mg, 7.5mg, 15mg, 20mg & 25mg Capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA171 Lenalidomide for treatment of Multiple Myeloma NICE TA 586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib NICE TA 587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma APC traffic light status: RED |
| POMALIDOMIDE | Tablets 1mg, 2mg, 3mg, 4mg | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA: Multiple myeloma previously treated with lenalidomide and bortezomib APC traffic light status: RED |
| THALIDOMIDE | 25mg tablet, 50mg capsule | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma APC traffic light status: RED |
| 7 TARGET THERAPY RESPONSIVE MALIGNANCY | ||
| BORTEZOMIB | 3.5mg vials for injection | Prescribing should be by an NHS specialist only, in line with NICE and/or local pathways. NHSE funded. NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma APC traffic light status: RED |
| CARFILZOMIB | 10mg, 30mg, 60mg vials | Prescribing should be by an NHS specialist only, in line with NICE and/or local pathways. NHSE funded. NICE TA457 – Carfilzomib for previously treated multiple myeloma APC traffic light status: RED |
| IXAZOMIB | 2.3mg, 3mg, 4mg capsules | Prescribing should be by an NHS specialist only, in line with NICE and/or local pathways. NHSE funded. IFR required. APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Protein Kinase Inhibitors | ||
| ABEMACICLIB | 50mg, 100mg, 150mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| ALECTINIB | 150mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer APC traffic light status: RED |
| BRIGATINIB | 30mg, 90mg, 180mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| BINIMETINIB | 15mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| CERITINIB | 150mg capsule | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA500 – Ceritinib for untreated ALK-positive non-small-cell lung cancer APC traffic light status: RED |
| CRIZOTINIB | 200mg, 250mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer APC traffic light status: RED |
| DABRAFENIB
| 50mg, 75mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NHSE Specialised Commissioning [DABRAFENIB] BRAF V600 melanoma APC traffic light status: RED |
| DACOMITINIB | 15mg, 30mg, 45mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA 595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer APC traffic light status: RED |
| DASATINIB | 20mg, 50mg, 80mg, 100mg, 140mg Tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA: Imatinib-resistant or intolerant CML APC traffic light status: RED |
| ENCORAFENIB | 50mg, 75mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| EVEROLIMUS | 5mg, 10mg Tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE through CDF. NICE TA : with exemestane for treating advanced breast cancer after endocrine therap APC traffic light status: RED |
| IBRUTINIB | 140mg Tablet | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE through CDF. NICE TA: Previously treated CLL and untreated CLL with 17p deletion or TP 53 mutation NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma NICE TA491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia APC traffic light status: RED |
| IDELALISIB | 100mg, 150mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA604: Idelalisib for treating refractory follicular lymphoma APC traffic light status: RED |
| IMATINIB | 100mg, 400mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA: Adjuvant treatment of GIST NICE TA: Imatinib-resistant or intolerant CML APC traffic light status: RED |
| LAROTRECTINIB | 20mg/ml oral solution | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE CDF. NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| LENVATINIB | 4mg, 10mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma APC traffic light status: RED |
| LORLATINIB | 25mg, 100mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. TA 628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| MIDOSTAURIN | 25mg Capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA523: Midostaurin for untreated acute myeloid leukaemia APC traffic light status: RED |
| NERATINIB | 40mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| NILOTINIB | 150mg, 200mg Capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA: Imatinib-resistant or intolerant CML APC traffic light status: RED |
| PALBOCICLIB | 75mg, 100mg, 125mg Capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| PONATINIB | 15mg, 45mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia APC traffic light status: RED |
| RIBOCICLIB | 200mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| SORAFENIB | 200mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| ANTINEOPLASTIC DRUGS – Other | ||
| NIRAPARIB | 100mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| RUCAPARIB | 200mg, 250mg, 300mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| OLAPARIB | 50mg capsules | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. APC traffic light status: RED |
| VENETOCLAX | 10mg, 50mg, 100mg tablets | Prescribing should be by a specialist only, in line with NICE and/or local pathways. Commissioned by NHSE. NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia APC traffic light status: RED |
| MEDROXYPROGESTERONE | Tablets 100 mg, 200 mg & 400 mg | . |
1. Gastro-Intestinal System | 2. Cardiovascular System | 3. Respiratory System | 4. Central Nervous System | 5. Antimicrobials | 6. Endocrine System | 7. Obstetrics, Gynaecology & Urology | 8. Malignant Disease & Immunosuppression | 9. Nutrition & Blood | 10. Musculoskelatal & Joint Diseases | 11. Opthalmology | 12. Ear, Nose & Oropharynx | 13. Dermatology | 14. Immunology & Vaccines | 15. Anaesthetics | GP Centre Home